Aligos Therapeutics (NASDAQ:ALGS) Third Quarter 2024 Results
Key Financial Results
Net loss: US$19.3m (loss widened by 6.8% from 3Q 2023).
NasdaqCM:ALGS Earnings and Revenue History November ...
Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments